A study published in the European Journal of Cancer shows that first-line treatment with everolimus provides some clinical benefit to patients with metastatic papillary renal cell carcinoma (pRCC). Treatment options are limited for these patients, which account for 10% to 15% of RCC cases.
The open-label phase 2 RAPTOR trial enrolled 92 previously untreated type 1 or type 2 metastatic pRCC patients. All patients were treated with everolimus, and there was no comparison group in the trial. Median progression-free survival was 4.1 months, median overall survival was 21.4 months, and 65% of patients achieved stable disease. Median progression-free survival and overall survival were longer for patients with type 1 than for type 2 papillary RCC.